SB-480848 in Major Adverse Cardiovascular Events - Integrated Phase III Summary of Efficacy and Safety
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2014
At a glance
- Drugs Darapladib (Primary)
- Indications Cardiovascular disorders; Coronary artery disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 02 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Sep 2013 Planned End Date changed from 1 Dec 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
- 17 Jul 2012 New trial record